Last reviewed · How we verify

Uriadec (TOPIROXOSTAT)

Senwa Kegaku Kenkyushp · FDA-approved active Small molecule Quality 17/100

Uriadec (generic name: TOPIROXOSTAT) is a Small molecule drug developed by Senwa Kegaku Kenkyushp. It is currently FDA-approved for Gout, Hyperuricemia.

At a glance

Generic nameTOPIROXOSTAT
SponsorSenwa Kegaku Kenkyushp
TargetATP-binding cassette sub-family G member 2, Xanthine dehydrogenase/oxidase, Xanthine dehydrogenase/oxidase
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Uriadec

What is Uriadec?

Uriadec (TOPIROXOSTAT) is a Small molecule drug developed by Senwa Kegaku Kenkyushp, indicated for Gout, Hyperuricemia.

What is Uriadec used for?

Uriadec is indicated for Gout, Hyperuricemia.

Who makes Uriadec?

Uriadec is developed and marketed by Senwa Kegaku Kenkyushp.

What is the generic name of Uriadec?

TOPIROXOSTAT is the generic (nonproprietary) name of Uriadec.

What development phase is Uriadec in?

Uriadec is FDA-approved (marketed).

What does Uriadec target?

Uriadec targets ATP-binding cassette sub-family G member 2, Xanthine dehydrogenase/oxidase, Xanthine dehydrogenase/oxidase.

Related